Type 2 Diabetes Causes Remodeling of Cerebrovasculature via Differential Regulation of Matrix Metalloproteinases and Collagen Synthesis
Role of Endothelin-1
- Alex K. Harris1,
- Jim R. Hutchinson1,
- Kamakshi Sachidanandam1,
- Maribeth H. Johnson2,
- Anne M. Dorrance3,
- David W. Stepp4,
- Susan C. Fagan1 and
- Adviye Ergul14
- 1Program in Clinical and Experimental Therapeutics, University of Georgia College of Pharmacy, Augusta, Georgia
- 2Department of Biostatistics, Medical College of Georgia, Augusta, Georgia
- 3Department of Physiology, Medical College of Georgia, Augusta, Georgia
- 4Vascular Biology Center, Medical College of Georgia, Augusta, Georgia
- Address correspondence and reprint requests to Adviye Ergul, MD, PhD, Medical College of Georgia, Clinical Pharmacy CJ-1020, Augusta, GA 30912. E-mail: aergul{at}mail.mcg.edu
Abstract
The risk of cerebrovascular disease is four- to sixfold higher in patients with diabetes. Vascular remodeling, characterized by extracellular matrix deposition and an increased media-to-lumen ratio, occurs in diabetes and contributes to the development of complications. However, diabetes-induced changes in the cerebrovascular structure remain unknown. Endothelin-1 (ET-1), a potent vasoconstrictor with profibrotic properties, is chronically elevated in diabetes. To determine diabetes-mediated changes in the cerebrovasculature and the role of ET-1 in this process, type 2 diabetic Goto-Kakizaki (GK) rats were administered an ETA receptor antagonist for 4 weeks. Middle cerebral arteries were harvested and studies were performed to determine vascular structure. Tissue and plasma ET-1 levels were increased in GK rats compared with controls. Significant medial hypertrophy and collagen deposition resulted in an increased wall-to-lumen ratio in diabetic rats that was reduced by ETA receptor antagonism. Vascular matrix metalloproteinase (MMP)-2 activity was higher, but MMP-1 levels were significantly reduced in GK rats, and MMP levels were restored to control levels by ETA receptor antagonism. We conclude that ET-1 promotes cerebrovascular remodeling in type 2 diabetes through differential regulation of MMPs. Augmented cerebrovascular remodeling may contribute to an increased risk of stroke in diabetes, and ETA receptor antagonism may offer a novel therapeutic target.
Footnotes
-
- Accepted June 8, 2005.
- Received March 3, 2005.
- DIABETES











